Cytoplasmic processing is a prerequisite for presentation of an endogenous antigen by major histocompatibility complex class II proteins

Journal of Experimental Medicine

Volumn 191, Issue 9, 2000, Pages 1513-1523

  Lich, John D ^a   Elliott, John F ^b   Blum, Janice S ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Calpain; Cathepsin; Cytoplasm; Protease; Proteasome

Indexed keywords

ASPARTIC PROTEINASE; CALPAIN; CYSTEINE PROTEINASE; CYTOPLASM PROTEIN; GLUTAMATE DECARBOXYLASE; HLA ANTIGEN CLASS 2; HLA DR4 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEASOME;

ACIDIFICATION; ANTIGEN BINDING; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CELL ORGANELLE; CONTROLLED STUDY; CYTOPLASM; ENDOSOME; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; LYSOSOME; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING;

ANTIGEN PRESENTATION; ASPARTIC ENDOPEPTIDASES; AUTOANTIGENS; BIOLOGICAL TRANSPORT; CELL POLARITY; CYSTEINE ENDOPEPTIDASES; CYTOPLASM; ENDOCYTOSIS; ENDOSOMES; GLUTAMATE DECARBOXYLASE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DR4 ANTIGEN; IMMUNODOMINANT EPITOPES; LYSOSOMES; PEPTIDE FRAGMENTS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SYNAPTIC VESICLES;

EID: 0034194155     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.191.9.1513     Document Type: Article

References (63)

1. Rudensky, A.Y., P. Preston-Hurlburt, S.-C. Hong, A. Barlow, and C.A. Janeway. 1991. Sequence analysis of peptides bound to MHC class II molecules. Nature. 353:622-627.
2. Chicz, R.M., R.G. Urban, J.C. Gorga, D.A.A. Vignali, W.S. Lane, and J.L. Strominger. 1993. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 178:27-47.
3. Griffin, J.P., R. Chu, and C.V. Harding. 1997. Early endosomes and a late endocytic compartment generate different peptide-class II MHC complexes via distinct processing mechanisms. J. Immunol. 158:1523-1532.
4. Rudensky, A.Y., S.M. Mazel, and V.L. Yurin. 1990. Presentation of endogenous immunoglobin determinant to immunoglobin-recognizing T cell clones by the thymic cells. Eur. J. Immnnol. 20:2235-2239.
5. Loss, G.E., C.G. Elias, P.E. Fields, R.K. Ribaudo, M. McKisic, and A.J. Sant. 1993. Major histocompatibility complex class II-restricted presentation of an internally synthesized antigen displays cell-type variability and segregates from the exogenous class II and endogenous class I presentation pathways. J. Exp. Med. 178:73-85.
6. Oehen, S., L. Feng, Y. Xia, C.D. Surh, and S.M. Hedrick. 1996. Antigen compartmentation and T helper cell tolerance induction. J. Exp. Med. 183:2617-2626.
7. Malnati, M.S., M. Marti, T. LaVaute, D. Jaraquemada, W. Biddison, R. DeMars, and E.O. Long. 1992. Processing pathways for presentation of cytosolic antigen to MHC class II-restricted T cells. Nature. 357:702-704.
8. Gueguen, M., and E.O. Long. 1996. Presentation of a cytosolic antigen by major histocompatibility complex class II molecules requires a long-lived form of the antigen. Proc. Natl. Acad. Sci. USA. 93:14692-14697.
9. Jondal, M., R. Schirmbeck, and J. Reimann. 1996. MHC class I-restricted CTL responses to exogenous antigens. Immunity. 5:295-302.
10. Reimann, J., and S.H. Kaufmann. 1997. Alternative antigen processing pathways in anti-infective immunity. Curr. Opin. Immunol. 9:462-469.
11. Harding, C.V. 1996. Class II antigen processing: analysis of compartments and functions. Crit. Rev. Immunol. 16:13-29.
12. Blum, J.S., M.L. Fiani, and P.D. Stahl. 1991. Proteolytic cleavage of ricin A chain in endosomal vesicles. J. Biol. Chem. 33:22091-22095.
13. Blum, J.S., and P. Cresswell. 1988. Role for intracellular proteases in the processing and transport of class II HLA antigens. Proc. Natl. Acad. Sci. USA. 85:3975-3979.
14. Mizuochi, T., S.-T. Yee, M. Kasai, D. Muno, and E. Kominami. 1994. Both cathepsin B and cathepsin D are necessary for the processing of ovalbumin as well as for the degradation of class II MHC invariant chain. Immunol. Lett. 43:189-193.
15. Hewitt, E.W., A. Treumann, N. Morrice, P.J. Tatnell, J. Kay, and C. Watts. 1997. Natural processing sites for human cathepsin E and cathepsin D in tetanus toxin. J. Immunol. 159: 4693-4699.
16. Lang, Y., F. Forquet, E. Speck, J. Blum, and T.L. Delovitch. 1996. Major histocompatibility complex class II molecules function as a template for the processing of a partially processed insulin peptide into a T-cell epitope. Diabetes. 45: 1711-1719.
17. Nakagawa, T., W. Roth, P. Wong, A. Nelson, A. Farr, J. Deussing, J.A. Villadangos, H. Ploegh, C. Peters, and A.Y. Rudensky. 1998. Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. Science. 280:450-453.
18. Jaraquemada, D., M. Marti, and E.O. Long. 1990. An endogenous processing pathway in vaccinia virus-infected cells for presentation of cytoplasmic antigens to class II-restricted T cells. J. Exp. Med. 172:947-954.
19. Lernmark, A. 1996. Glutamic acid decarboxylase - gene to antigen to disease. J. Intern. Med. 240:259-277.
20. Wicker, L.S., S.-L. Chen, G.T. Nepom, J.F. Elliott, D.C. Freed, A. Bansai, S. Zhen, A. Herman, A. Lernmark, D.M. Zaller, et al. 1996. Naturally processed T cell epitopes from human glutamic acid decarboxylase identified using mice transgenic for the type I diabetes-associated human MHC class II allele, DRB1*0401. J. Clin. Invest. 98:2597-2603.
21. Elliott, J.F., H.-Y. Qin, S. Bhatti, D.K. Smith, R.K. Singh, T. Dillon, J. Lauzon, and B. Singh. 1994. Immunization with the larger isoform of mouse glutamic acid decarboxylase (GAD67) prevents autoimmune diabetes in NOD mice. Diabetes. 43:1494-1499.
22. Christgau, S., H. Schierbeck, H.-J. Aanstoot, L. Aagaard, K. Begley, H. Kofo, K. Hejnaes, and S. Baekkeskov. 1991. Pancreatic beta-cells express two autoantigenic forms of glutamic acid decarboxylase, a 65-kDa hydrophilic form and a 64-kDa amphiphilic form which can be both membrane-bound and soluble. J. Biol. Chem. 266:21257-21264.
23. Chang, Y.-C., and D.I. Gottlieb. 1988. Characterization of the proteins purified with monoclonal antibodies to glutamic acid decarboxylase. J. Neurosci. 8:2123-2130.
24. Dugas, B., J.M. Mencia-Huerta, P. Braquet, P. Galanaud, and J.F. Delfraissy. 1989. Extracellular but not intracellular calcium mobilization is required for Epstein-Barr virus-containing supernatant-induced B cell activation. Eur. J. Immunol. 19:1867-1871.
25. Oxenius, A., M.F. Bachmann, P.G. Ashton-Rickardt, S. Tonegawa, R.M. Zinkernagel, and H. Hengartner. 1995. Presentation of endogenous viral proteins in association with major histocompatibility complex class II: on the role of intracellular compartmentalization, invariant chain and the TAP transporter system. Eur. J. Immunol. 25:3402-3411.
26. Pinet, V., M.S. Malnati, and E.O. Long. 1994. Two processing pathways for the MHC class II restricted presentation of exogenous influenza virus antigens. J. Immunol. 152:4852-4860.
27. St.-Pierre, Y., and T.H. Watts. 1990. MHC class II-restricted presentation of native protein antigens by B cells is inhibitable by cycloheximide and brefeldin A. J. Immunol. 145:812-818.
28. Nuchtern, J.G., W.E. Biddison, and R.D. Klausner. 1990. Class II MHC molecules can use the endogenous pathway of antigen presentation. Nature. 343:74-76.
29. Ramachandra, L., R. Song, and C.V. Harding. 1999. Phagosomes are fully competent antigen-processing organelles that mediate the formation of peptide:class II MHC complexes. J. Immunol. 162:3263-3272.
30. Ullrich, H.J., K. Doring, U. Gruneberg, F. Jahnig, J. Trowsdale, and S.M. van Ham. 1997. Interaction between HLA-DM and HLA-DR involves regions that undergo conformational changes at lysosomal pH. Proc. Natl. Acad. Sci. USA. 94:13163-13168.
31. Pinet, V.M., and E.O. Long. 1998. Peptide loading onto recycling HLA-DR molecules occurs in early endosomes. Eur. J. Immunol. 28:799-804.
32. McConnell, R., J.L. York, D. Frizzell, and C. Ezell. 1993. Inhibition studios of some serine and thiol proteinases by new leupeptin analogues. J. Med. Chem. 36:1084-1089.
33. Illy, C., O. Quraishi, J. Wang, E. Purisima, T. Vernet, and J.S. Mort. 1997. Role of the occluding loop in cathepsin B activity. J. Biol. Chem. 272:1197-1202.
34. Rock, K.L., C. Gramm, L. Rothstein, K. Clark, R. Stein, L. Dick, D. Hwang, and A.L. Goldberg. 1994. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell. 78:761-771.
35. Cerundolo, V., A. Benham, V. Braud, S. Mukherjee, K. Gould, B. Macino, J. Neefjes, and A. Townsend. 1997. The proteasome-specific inhibitor lactacystin blocks presentation of cytotoxic lymphocyte epitopes in human und murine cells. Eur. J. Immunol. 27:336-341.
36. Vinitsky, A., L.C. Anton, H.L. Snyder, M. Orlowski, J.R. Bennink, and J.W. Yewdell. 1997. The generation of MHC class I-associated peptides is only partially inhibited by proteasome inhibitors. J. Immunol. 159:554-564.
37. Lopez, D., and M.D. Val. 1997. Cutting edge: selective involvement of proteasomes and cysteine proteases in MHC class I antigen presentation. J. Immunol. 159:5769-5772.
38. Sorimachi, H., S. Ishiura, and K. Suzuki. 1997. Structure and physiological function of calpains. Biochem. J. 328:721-732.
39. Gopalakrishna, R., and S.H. Barsky. 1986. Hydrophobic association of calpains with subcellular organelles. J. Biol. Chem. 261:13936-13942.
40. Yano, Y., E. Shiba, J.-I. Kambayashi, M. Sakon, T. Kawasaki, K. Fujitani, J. Kang, and T. Mori. 1993. The effects of calpeptin (a calpain specific inhibitor) on agonist induced microparticle formation from the platelet plasma membrane. Thromb. Res. 71:385-396.
41. Fox, J.E.B., C.D. Austin, C.C. Reynolds, and P.K. Steffen. 1991. Evidence that agonist-induced activation of calpain causes the shedding of procoagulant-containing microvesicles from the membrane of aggregating platelets. J. Biol. Chem. 266:13289-13295.
42. Wang, K.K.W., R. Nath, A. Posner, K.J. Raser, M. Buroker-Kilgore, I. Hajimohammadreza, A.W. Probert, Jr., F.W. Marcoux, Q. Ye, E. Takano, et al. 1996. An alpha-mercaptoacrylic acid derivative is a selective nonpeptide cell-permeable calpain inhibitor and is neuroprotective. Proc. Natl. Acad. Sci. USA. 93:6687-6692.
43. Lukas, J., J. Bartek, and M. Strauss. 1994. Efficient transfer of antibodies into mammalian cells by electroporation. J. Immunol. Methods. 170:255-259.
44. Deshpande, R.V., J.-M. Goust, A.K. Chakrabarti, E. Barbosa, E.L. Hogan, and N.L. Banik. 1995. Calpain expression in lymphoid cells. J. Biol. Chem. 270:2497-2505.
45. Blum, J.S. 1998. Bare lymphocyte syndrome. In Encyclopedia of Immunology. P.J. Delves and I. Roth, editors. Academic Press, London. 329-332.
46. Battegay, M., M.F. Bachmann, C. Burhkart, S. Viville, C. Benoist, D. Mathis, H. Hengartner, and R.M. Zinkernagel. 1996. Antiviral immune responses of mice lacking MHC class II or its associated invariant chain. Cell. Immunol. 167:115-121.
47. Hiltbold, E.M., S.A. Safley, and H.K. Ziegler. 1996. The presentation of class I and class II epitopes of listeriolysin O is regulated by intracellular localization and intercellular spread of Listeria monocytogenes. J. Immunol. 157:1163-1175.
48. Lord, E.M., and J.G. Frelinger. 1998. Tumor immunotherapy: cytokines and antigen presentation. Cancer Immunol. Immunother. 46:75-81.
49. Vyse, T.J., and J.A. Todd. 1946. Genetic analysis of autoimmune disease. Cell. 85:311-318.
50. Falcone, M., J. Lee, G. Patstone, B. Yeung, and N. Sarvetnick. 1998. B lymphocytes are crucial antigen-presenting cells in the pathogenic autoimmune response to GAD65 antigen in nonobese diabetic mice. J. Immunol. 161:1163-1168.
51. Tian, J., M.A. Atkinson, M. Clare-Salzer, A. Herschenfeld, T. Forstuber, P.V. Lehmann, and D.L. Kaufman. 1996. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J. Exp. Med. 183:1561-1567.
52. Nakagawa, T.Y., W.H. Brissette, P.D. Lira, R.J. Griffiths, N. Petrushova, J. Stock, J.D. McNeish, S.E. Eastman, E.D. Howard, S.R.M. Clarke, et al. 1999. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity. 10:207-217.
53. Deussing, J., W. Roth, P. Saftig, C. Peters, H.L. Ploegh, and J.A. Villadangos. 1998. Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. Proc. Natl. Acad. Sci. USA. 95:4516-4521.
54. Shi, G.-P., J.A. Villadangos, G. Dranoff, C. Small, L. Gu, K.J. Haley, R. Riese, H.L. Ploegh, and H.A. Chapman. 1999. Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity. 10:197-206.
55. Brooks, A.G., and J. McClusky. 1993. Class II-restricted presentation of a hen egg lysozyme determinant derived from endogenous antigen sequestered in the cytoplasm or endoplasmic reticulum of the antigen presenting cells. J. Immunol. 150:3690-3697.
56. Bachmair, A., D. Finley, and A. Varshavsky. 1986. In vivo half-life of a protein is a function of its amino-terminal residue. Science. 234:179-186.
57. Kisselev, A., T. Akopian, K. Woo, and A. Goldberg. 1999. The size of peptides generated from protein by mammalian 26 and 20S proteasomes. Implications for understanding the degradative mechanisms and antigen presentation. J. Biol. Chem. 274:3363-3371.
58. Mo, X.Y., P. Cascio, K. Lemerise, A.L. Goldberg, and K. Rock. 1999. Distinct proteolytic processes generate the C and N termini of MHC class I-binding peptides. J. Immunol. 163:5851-5859.
59. Chen, F., Y. Lu, D.C. Kuhn, M. Maki, X. Shi, S.-C. Sun, and L.M. Demers. 1997. Calpain contributes to silica-induced I-kappa-B-alpha degradation and nuclear factor kappa-B activation. Arch. Biochem. Biophys. 342:383-388.
60. Noguchi, M., A. Sarin, M.J. Aman, H. Nakajima, E.W. Shores, P.A. Henkart, and W.J. Leonard. 1997. Functional cleavage of the common cytokine receptor gamma chain by calpain. Proc. Natl. Acad. Sci. USA. 94:11534-11539.
61. Wang, K.K.W., and P.-W. Yuen. 1994. Calpain inhibition: an overview of its therapeutic potential. Trends Pharmacol. Sci. 15:412-419.
62. Malnati, M., S. Ceman, M. Weston, R. DeMars, and E. Long. 1993. Presentation of cytosolic antigen by HLA-DR requires a function encoded in the class II region of the MHC. J. Immnnol. 151:6751-6756.
63. Agarraberes, F.A., S.R. Terlecky, and J.F. Dice. 1997. An intralysosomal hsp70 is required for a selective pathway of lysosomal protein degradation. J. Cell Biol. 137:825-834.